We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis spin-off Alcon will pick up Aerie Pharmaceuticals, expanding Alcon’s eye care products focus into the prescription pharmaceuticals arena. Read More
Catalent announced that it will shell out $475 million to acquire Metrics Contract Services, a specialty contract development and manufacturing organization (CDMO) with a 333,000 square-foot facility in Greenville. Read More
GlaxoSmithKline (GSK) and clinical-stage biopharma company Mersana Therapeutics have forged a global collaboration, giving GSK the exclusive option to codevelop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056 targeting HER2. Read More
Regeneron Pharmaceuticals has sued Viatris over the company’s proposed biosimilar of Regeneron’s blockbuster vision loss drug, saying it violates multiple patents. Read More
Pfizer announced that it will pay $5.4 billion for Global Blood Therapeutics (GBT), manufacturer of Oxbryta (voxelotor), one of a handful of drugs for treating sickle cell anemia. Read More
Amgen announced that it is acquiring ChemoCentryx, a developer of oral therapies to treat autoimmune diseases, inflammatory disorders and cancer, for approximately $3.7 billion. Read More